A5060158935- Nanoparticle-Based Drug Delivery
- Nanoplatforms for cancer theranostics
- Cancer Treatment and Pharmacology
- RNA Interference and Gene Delivery
- Radiopharmaceutical Chemistry and Applications
- Chemotherapy-induced cardiotoxicity and mitigation
- Advanced biosensing and bioanalysis techniques
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Graphene and Nanomaterials Applications
- Monoclonal and Polyclonal Antibodies Research
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Lipid Membrane Structure and Behavior
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
Shaare Zedek Medical Center
2016-2025
Hebrew University of Jerusalem
2015-2025
Bikur Cholim Hospital
2007-2023
Rabin Medical Center
1987-2023
Meir Medical Center
2023
Inovio Pharmaceuticals (United States)
2022
GTx (United States)
2017
Memorial Sloan Kettering Cancer Center
2016
Brigham and Women's Hospital
2013
National Cancer Institute
2013
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have pronounced effect on tissue distribution and can produce large increase the pharmacological efficacy of encapsulated antitumor drugs. This is substantially greater than observed previously with conventional liposomes associated more 5-fold prolongation circulation time blood, marked decrease uptake by tissues such as liver spleen, corresponding...
Enhanced permeability of the tumor vasculature allows macromolecules to enter interstitial space, whereas suppressed lymphatic filtration them stay there. This phenomenon, enhanced and retention (EPR), has been basis nanotechnology platforms deliver drugs tumors. However, progress in developing effective using this approach hampered by heterogeneity EPR effect different tumors limited experimental data from patients on effectiveness mechanism as related drug accumulation. report summarizes...
The rapid clearance of circulating liposomes from the bloodstream, coupled with their high uptake by liver and spleen, has thus far been an obstacle to any attempts at targeting tumors. We have assessed impact liposome composition on circulation in normal tumor-bearing mice tumors various tissues. By selective changes lipid composition, while maintaining a mean particle diameter approximately equal 100 nm, we achieved up 60-fold increase fraction recovered dose present blood 24 hr after i.v....
Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of in poly(ethylene glycol)-coated (stealth) liposomes with prolonged circulation time and unique toxicity profile. We review the preclinical clinical pharmacology as well recent data obtained specific cancer types. Doxil retain drug payload during accumulate preferentially tissues increased microvascular permeability, often case tumors. profile drastically different from that doxorubicin, characterized by dominant...
PURPOSE The purpose of our studies was to define the maximal-tolerated dose liposomal doxorubicin (DOX-SL; Liposome Technology Inc, Menlo Park, CA), a formulation polyethyleneglycol-coated liposomes, characterize toxicities associated with this formulation, and evaluate any indication antitumor activity within phase I setting. PATIENTS AND METHODS Two separate were conducted following initial human pharmacokinetic testing at one sites (Hadassah). starting 20 mg/m2 University Southern...
Conjugates of three components, folic acid−poly(ethylene glycol)−distearoylphosphatidylethanolamine (FA−PEG−DSPE), derived from PEG with molecular masses 2000 and 3350 Da were synthesized by a carbodiimide-mediated coupling FA to H2N-PEG−DSPE. The conjugates characterized 1H NMR, MALDI-TOF, HPLC analysis enzymatic cleavage carboxypeptidase G. As prototype folate receptor (FR)-targeted system, the formulated at 0.5 mol % phospholipid in hydrogenated phosphatidylcholine/cholesterol liposomes...
Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging treatment cancers, resulting several promising candidates clinical trials. Despite these advances, applications nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, translational barriers. In order to overcome existing status quo drug delivery, there is a need open frank discussion nanomedicine community on what needed make qualitative...
In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting several approved drugs multiple promising candidates clinical trials. Regulatory agencies such as the Food Drug Administration European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly context of liposomes lipid-based carriers. Even with achieved, it is clear that many barriers must still be overcome...